The European Patent Office (EPO) has granted patent EP3439682B1, titled "HYPERSENSITIVE RESPONSE ELICITOR-DERIVED PEPTIDES AND USE THEREOF." This patent, effective March 18, 2026, covers specific peptide sequences and their applications, particularly in the context of plant defense mechanisms. The grant signifies the EPO's recognition of the novelty and inventiveness of the claimed peptides.

This patent grant is primarily relevant for entities involved in biotechnology research and development, particularly those working with plant defense peptides or seeking to develop new agricultural or pharmaceutical products based on these compounds. While this is a patent grant and not a regulatory rule imposing direct compliance obligations, it establishes intellectual property rights that may affect market exclusivity and licensing opportunities for related products. Companies operating in this space should be aware of this granted patent and its potential implications for their research and commercial strategies.